Shijiazhuang Yiling Pharmaceutical Co. Ltd
15
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
27%
4 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Role: lead
A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men
Role: lead
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Role: lead
A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours
Role: lead
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Role: lead
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Role: lead
A Phase Ⅲ Clinical Study Trial of Felbinac Trometamol Injection in China
Role: lead
A Phase # Clinical Study Trial of Felbinac Trometamol Injection in China
Role: lead
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Role: lead
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
Role: lead
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
Role: lead
A Phase Ⅱ Clinical Study Trial of Felbinac Trometamol Injection in China
Role: lead
A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China
Role: lead
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Role: collaborator
Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)
Role: collaborator
All 15 trials loaded